When was Alpha-9 Oncology founded?

Alpha-9 Oncology was founded in 2018 and raised its 1st funding round 3 years after it was founded.

Where is Alpha-9 Oncology located?

Alpha-9 Oncology is headquartered in Boston, United States.

How many employees does Alpha-9 Oncology have?

As of Sep 30, 2026, the latest employee count at Alpha-9 Oncology is 47.

Is Alpha-9 Oncology a funded company?

Alpha-9 Oncology is a funded company, having raised a total of $261M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 28, 2021.

When was the latest funding round of Alpha-9 Oncology?

Alpha-9 Oncology's latest funding was a $***** Series C round on Oct 23, 2024, with participation from 14 investors.

Where does Alpha-9 Oncology rank among its competitors?

Alpha-9 Oncology ranks 627th amongst 2519 active competitors, of which 864 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Alpha-9 Oncology?

Alpha-9 Oncology's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Alpha-9 Oncology - 2026 Company Profile, Funding & Competitors

Alpha-9 Oncology is a series C company based in Boston (United States), founded in 2018. It operates as a Developer of radiopharmaceuticals for the treatment of cancer. Alpha-9 Oncology has raised $261M in funding from investors like Lightspeed Venture Partners, Longitude Capital and Nextech Invest. The company has 2519 active competitors, including 864 funded and 626 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of radiopharmaceuticals for the treatment of cancer. The company applies radiotherapeutic design by a toolbox of technologies for peptide-based radiopharmaceuticals to deliver radiation to cancer cells for the treatment of people living with cancer.

Website: a9oncology.com
Email ID: *****@a9oncology.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Boston, United States

Stage

Series C

Total Funding

$261M in 3 rounds

Latest Funding Round

Series C, Oct 23, 2024, $*****

Investors

Lightspeed Venture Partners & 15 more

Ranked

627^th among 2519 active competitors

Employee Count

47 as on Sep 30, 2026

Similar Companies

Molecular Partners & 101 more

View Alpha-9 Oncology's full profile

Alpha-9 Oncology has raised a total funding of $261M over 3 rounds. Its first funding round was on Apr 28, 2021. Its latest funding round was a Series C round on Oct 23, 2024 for $*****. 14 investors participated in its latest round. Alpha-9 Oncology has 15 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Alpha-9 Oncology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 23, 2024	7526557	Series C	9152616	3065314	9357574	4189943
Dec 14, 2022	1925652	Series B	7474148	2452947	3195388	Frazier Life Sciences & 4 more
Apr 28, 2021	9142827	Series A	4003164	3447908	Longitude Capital	BVF Partners

Access funding benchmarks and valuations. Sign up today!

View details of Alpha-9 Oncology's funding rounds and investors

Alpha-9 Oncology's employee count trend

Alpha-9 Oncology has 47 employees as of Sep 26. Here is Alpha-9 Oncology's employee count trend over the years:

Employee count trend for Alpha-9 Oncology

Uncover Alpha-9 Oncology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alpha-9 Oncology include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Alpha-9 Oncology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
627th	Alpha-9 Oncology 2018, Boston (United States), Series C	Developer of radiopharmaceuticals for the treatment of cancer	$261M	BVF Partners, Nextech Invest & 14 others	42/100